Drug Profile

Research programme: prostate cancer therapy - BPG Bio/CPDR/HJF

Latest Information Update: 26 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Berg Pharma; Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences
Developer BPG Bio; Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences
Class Antineoplastics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 Aug 2025 Discontinued for Prostate cancer in USA (unspecified route) before August 2025 (BPG Bio pipeline, August 2025)
28 Jul 2018 No recent reports of development identified for research development in Prostate-cancer in USA
09 Aug 2013 Early research in Prostate cancer in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com